Reflection paper on clinical aspects related to tissue engineered products

We have adopted this International Scientific Guideline - EMA/CAT/573420/2009

Last updated

23 December 2024

Overseas effective date: 19 December 2014

Provided for information: 1 September 2015

Note: This reflection paper is intended as a supplement to the Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006)

Categories: Multidisciplinary | Cell therapy and tissue engineering

TGA Annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency - external site for further information.

Topics

Help us improve this page